Saving the Lives of People with Blood Cancer
by
After the news that the Scottish Medicine Consortium has recommended letermovir (Prevymis) for routine use on the NHS in Scotland, Bradley from our Policy and Public Affairs team shares what this means for patients and how Anthony Nolan promoted the views and experiences of patients to help make this happen. A new preventative treatment The…
by
Jonathan in our patient services team discusses emerging treatments for cancer, using cell therapy and new ‘super cells’. When developing a new cancer treatment, one of the most important things to consider is how well it can be tolerated by patients. Often the amount of drug that can be given is limited by the side…
by
This week, the NHS released a long-term plan setting out its priorities for the service over the next ten years. This followed the government’s announcement to increase NHS funding by £20 billion a year by 2023. Please note that these plans only relate to NHS England, and the devolved nations will have control of their extra funding. Our Policy and Public Affairs Officer, Bradley Price, explains everything…
by
Jonathan in the Patient Services team discusses recent research into the use of cell therapies to treat Graft versus Host Disease (GvHD), which is a common side effect of stem cell transplant. He also looks at the implications this may have for patients whose symptoms have not responded to standard treatments. Graft vs Host…
by
Today (14 September 2017), we’ve launched a new campaign, ‘Who Cares?’ calling for an urgent review of the care and support that patients receive after a stem cell transplant. Our Policy and Public Affairs Manager, Amelia Chong, explains everything you need to know about the campaign and how you can help. Why we’re…
by
On 18 July, Anthony Nolan was in Parliament to spread the word about why stem cell transplantation matters and how local communities can get involved. Thousands of you asked your MP to attend. The Campaigns Team explains what happened at the event, and the impact an email from campaigners and communities can have on an…
